RENOVORX INC (RNXT) Stock News

These stocks are moving in today's pre-market session

The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Mentions: BOOM THRD PTN FLL ...

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

12 Health Care Stocks Moving In Monday's After-Market Session

Mentions: AGL HUM PCRX OGEN ...

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Proposed Public Offering

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System

Over Ten Medical Institutions Nationwide have Initiated RenovoCath Purchase Process, Further Accelerating Commercialization Strategy RenovoRx Estimates...

12 Health Care Stocks Moving In Monday's Pre-Market Session

Mentions: IBO BMRA SNTI NVCR ...

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in...

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights...

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of...

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York

LOS ALTOS, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical...

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Phase III clinical trial is evaluating RenovoGem™ for the treatment of Locally Advanced Pancreatic Cancer UNMC opened enrollment of TIGeR-PaC in June 2024...

RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024

RNXT stock results show that RenovoRx met analyst estimates for earnings per share the second quarter of 2024.

RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips RenovoRx (NASDAQ:RNXT) just reported results for the second quarter of 2024.Ren...

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

Publication of data relating to RenovoRx’s targeted therapy platform to treatment of Locally Advanced Pancreatic Cancer (LAPC) is expected to be in the...

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial

Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer...